Recommended treatment for men with metastatic prostate cancer could be turned on its ear by a clinical trial spanning five countries and led by Dr. Isaac Kim, professor and department chair of the ...

ASTRO released a clinical practice guideline with evidence-based recommendations for palliative radiation therapy for ...

Finally, because the median survival after developing bone metastases ranges from 6 to 48 months depending on tumor type, bone metastases cause chronic morbidity that often requires repeated ...

Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment ... the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with zoledronic ...

For example, individuals may have discomfort or fractures if the cancer has migrated to their bones. Breathing difficulties, ...

If you consistently experience any of these symptoms, it’s important to alert your cancer care team as soon as possible. To diagnose brain metastases, your doctor will most likely perform a ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...